2025 年全球遗传性癌症检测市场报告

预计未来几年遗传性癌症检测市场将快速成长。到 2029 年，这一数字将成长到 73.7 亿美元，年复合成长率（CAGR）为 11.4%。预测期内的增长可归因于标靶治疗的扩展、精准医疗的进步、直接面向消费者的测试的增加、全球健康计划以及生物资讯学的进步。预测期内的主要趋势包括基因序列测定技术的进步、远端医疗和远距遗传咨询、精准医疗和个人化治疗、癌症风险评估模型以及道德和法律考虑。

由于遗传性癌症发生率的不断上升，遗传性癌症检测市场正在经历显着的增长。正如 2022 年 6 月的一篇关于临床实践中的遗传性癌症的报导所强调的那样，大约 10% 的胰腺癌病例具有遗传背景。遗传性癌症检测需求量很大，因为它可以检测与遗传性癌症症候群相关的特定基因突变，并有助于全面的癌症风险评估。这一趋势凸显了遗传性癌症检测在应对遗传性癌症带来的挑战中所扮演的重要角色。

由于癌症整体负担的增加，遗传性癌症检测市场预计将显着增长。癌症以细胞异常增生为特征，是全球面临的重大健康挑战。透过识别具有特定癌症遗传易感性的个体，遗传性癌症检测已成为减轻这种负担的重要工具。这使得早期疗育、个人化治疗策略和预防措施成为可能。根据欧盟科学中心 2023 年 10 月的一篇报导，预计 2022 年新发癌症病例将增加 2.3%，达到 274 万例，而癌症相关死亡人数将比 2020 年增加 2.4%。癌症病例的快速增加凸显了遗传性癌症检测作为癌症综合办法的一部分的日益增长的需求。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第 4 章 市场：宏观经济情景，包括利率、通膨、地缘政治、新冠疫情以及復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球遗传性癌症检测PESTEL分析（政治、社会、科技、环境、法律、驱动因素、限制因素）
• 最终用途产业分析
• 全球遗传性癌症检测市场：成长率分析
• 全球遗传性癌症检测市场表现：规模与成长，2019 年至 2024 年
• 全球遗传性癌症检测市场预测：规模与成长，2024-2029 年，2034 年
• 全球遗传性癌症检测总潜在市场 (TAM)

第六章 市场细分

• 全球遗传性癌症检测市场：按检测类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
• 多面板检查
• 单点基因检测
• 全球遗传性癌症检测市场：依适应症、表现与预测，2019-2024 年、2024-2029 年、2034 年
• 乳癌
• 卵巢癌
• 大肠直肠癌
• 其他适应症
• 全球遗传性癌症检测市场：按最终用户、绩效和预测，2019-2024 年、2024-2029 年、2034 年
• 医院
• 诊所
• 诊断中心
• 全球遗传性癌症检测市场：多面板检测细分、类型、表现和预测，2019-2024 年、2024-2029 年、2034 年
• 综合基因组
• 标靶基因面板
• 全球遗传性癌症检测市场：单点基因检测细分市场、类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 某些基因测试
• 遗传性性突变检测

第七章 区域和国家分析

• 全球遗传性癌症检测市场：按地区、表现和预测，2019-2024 年、2024-2029 年、2034 年
• 全球遗传性癌症检测市场：依国家划分、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第 17 章 德国市场

第 18 章 法国市场

第 19 章：义大利市场

第 20 章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第 25 章：加拿大市场

第26章 南美洲市场

第 27 章：巴西市场

第28章 中东市场

第 29 章：非洲市场

第 30 章竞争格局与公司概况

• 遗传性癌症检测市场：竞争格局
• 遗传性癌症检测市场：公司简介
  • Centogene NV Overview, Products and Services, Strategy and Financial Analysis
  • Ambry Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • NeoGenomics Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

• PreventionGenetics
• Fulgent Genetics Inc.
• Invitae Corporation
• Medical Diagnostic Laboratories LLC
• Natera Inc.
• Color Health Inc.
• CooperSurgical Inc.
• OPKO Health Inc.
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Pathway Genomics Corporation
• Strand Life Sciences Private Limited
• Progenity Inc.
• Myogenes Ltd.
• Associated Regional and University Pathologists Inc.

第 32 章 全球市场竞争基准化分析与仪表板

第33章 重大併购

第 34 章 近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

• 2029 年遗传性癌症检测市场：提供新机会的国家
• 2029 年遗传性癌症检测市场：细分市场将带来新机会
• 遗传性癌症检测市场 2029：成长策略
  • 基于市场趋势的策略
  • 竞争对手的策略

第 36 章 附录

Hereditary cancer testing involves various testing methods designed for identifying specific hereditary cancer diseases and gene mutations associated with these diseases. These tests play a crucial role in assessing the risk of developing certain cancer types with a genetic predisposition, enabling a more comprehensive understanding of cancer risk for patients. The primary objective of hereditary cancer testing is early detection, allowing for proactive measures to minimize the risk and improve overall health outcomes for individuals.

There are two main types of tests for hereditary cancer such as multi-panel tests and single-site genetic tests. Multi-panel tests simultaneously examine multiple genes associated with different types of cancers. These panels can vary in size, ranging from three-panel tests targeting specific substances to more extensive panels with five, seven, or even 12 tests, providing a broader analysis of genetic risk factors. The decision on the number of tests conducted is based on the discretion of the tester. Hereditary cancer testing is applicable to detect various types of cancers, including breast cancer, ovarian cancer, colorectal cancer, and others. These tests are typically conducted in hospitals, clinics, and diagnostic centers.

The hereditary cancer testing market research report is one of a series of new reports from The Business Research Company that provides hereditary cancer testing market statistics, including hereditary cancer testing industry global market size, regional shares, competitors with a hereditary cancer testing market share, detailed hereditary cancer testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary cancer testing industry. This hereditary cancer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary cancer testing market size has grown rapidly in recent years. It will grow from $4.32 billion in 2024 to $4.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rising incidence of hereditary cancers, genetic counseling programs, government initiatives for cancer prevention, improved insurance coverage, understanding of gene-environment interactions, patient advocacy and support groups.

The hereditary cancer testing market size is expected to see rapid growth in the next few years. It will grow to $7.37 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to expansion of targeted therapies, advancements in precision medicine, rise in direct-to-consumer testing, global health initiatives, advancements in bioinformatics. Major trends in the forecast period include advancements in genetic sequencing technologies, telemedicine and remote genetic counseling, precision medicine and personalized treatment, cancer risk assessment models, ethical and legal considerations.

The hereditary cancer testing market is experiencing substantial growth due to the increasing prevalence of hereditary cancer. As highlighted in a June 2022 article on hereditary cancer in clinical practice, approximately 10% of pancreatic cancer cases have a genetic background. The demand for hereditary cancer testing is escalating as it enables the detection of specific gene mutations associated with hereditary cancer syndromes, facilitating comprehensive cancer risk assessments. This trend underscores the pivotal role of hereditary cancer testing in addressing the challenges posed by hereditary cancer.

The hereditary cancer testing market is set to witness significant growth driven by the increasing overall burden of cancer. Cancer, characterized by abnormal cell growth, poses a substantial health challenge globally. Hereditary cancer testing emerges as a crucial tool in mitigating this burden by identifying individuals with a genetic predisposition to specific cancers. This allows for early interventions, personalized treatment strategies, and proactive preventive measures. According to the EU Science Hub's October 2023 article, new cancer cases rose by 2.3%, reaching 2.74 million in 2022, and cancer-related deaths increased by 2.4% compared to 2020. The surge in cancer cases highlights the growing need for hereditary cancer testing as part of a comprehensive approach to cancer management.

Technological innovation is a key trend influencing the hereditary cancer testing market, with major players focusing on advancements to maintain their market positions. In March 2022, Myriad Genetics, a prominent US-based genetic testing and precision medicine company, introduced a Polygenic Breast Cancer Risk Assessment Score for all ancestries as part of its MyRisk Hereditary Cancer test with RiskScore. This innovative approach offers a personalized breast cancer risk assessment to women without a previous breast cancer diagnosis, showcasing the industry's commitment to leveraging technology for enhanced testing capabilities and individualized risk evaluations.

Major companies operating in the hereditary cancer testing market are focusing on innovative technologies such as molecular diagnostic tumor testing to improve accuracy, enhance patient outcomes, and enable personalized treatment strategies. Molecular diagnostic tumor testing involves analyzing the genetic and molecular profile of a tumor to guide treatment decisions and predict outcomes. For instance, in 2023, Chubb Business Services India Private Limited, an India-based global insurance company, launched Cancer Advocate Plus. This program includes genetics-based testing to identify inherited genes that increase cancer risk, enabling individuals to understand their cancer susceptibility and allowing for early intervention and personalized care strategies.

In January 2022, Exact Sciences, a U.S.-based molecular diagnostics company, successfully completed the acquisition of PreventionGenetics for approximately $190 million. This strategic acquisition enhances Exact Sciences' portfolio of advanced cancer tests by incorporating PreventionGenetics' comprehensive genetic testing offerings, creating a complementary synergy. PreventionGenetics brings to the table not only a diverse genetic testing portfolio but also valuable clinical lab capabilities, expertise, and foundational technology. This collaboration aims to accelerate the availability of Hereditary Cancer Testing (HCT) and extend the reach of genetic risk assessment for cancer and other diseases. PreventionGenetics is a U.S.-based genetic testing and DNA testing laboratory.

Major companies operating in the hereditary cancer testing market are Centogene NV, Ambry Genetics Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, PreventionGenetics, Fulgent Genetics Inc., Invitae Corporation, Medical Diagnostic Laboratories LLC, Natera Inc., Color Health Inc., CooperSurgical Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes Ltd., Associated Regional and University Pathologists Inc., 4baseCare, Biocartis Group NV, F. Hoffmann-La Roche AG, Medgenome Pvt. Ltd., Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies PLC, PerkinElmer Inc.

North America was the largest region in the hereditary cancer testing market in 2024. The regions covered in the hereditary cancer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hereditary cancer testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary cancer testing market includes revenues earned by entities by providing hereditary cancer testing for lung cancer, cervical cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, and uterine cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Cancer Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary cancer testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary cancer testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary cancer testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Multi Panel Test; Single-Site Genetic Test
• 2) By Indication: Breast Cancer; Ovarian Cancer; Colorectal Cancer; Other Indications
• 3) By End user: Hospital; Clinics; Diagnostic Centers
• Subsegments:
• 1) By Multi Panel Test: Comprehensive Genetic Panels; Targeted Gene Panels
• 2) By Single-Site Genetic Test: Specific Gene Testing; Familial Mutation Testing
• Companies Mentioned: Centogene NV; Ambry Genetics Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; Quest Diagnostics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Cancer Testing Market Characteristics

3. Hereditary Cancer Testing Market Trends And Strategies

4. Hereditary Cancer Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hereditary Cancer Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hereditary Cancer Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hereditary Cancer Testing Market Growth Rate Analysis
• 5.4. Global Hereditary Cancer Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hereditary Cancer Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hereditary Cancer Testing Total Addressable Market (TAM)

6. Hereditary Cancer Testing Market Segmentation

• 6.1. Global Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multi Panel Test
• Single-site Genetic Test
• 6.2. Global Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Ovarian Cancer
• Colorectal Cancer
• Other Indications
• 6.3. Global Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• Diagnostic Centers
• 6.4. Global Hereditary Cancer Testing Market, Sub-Segmentation Of Multi Panel Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Comprehensive Genetic Panels
• Targeted Gene Panels
• 6.5. Global Hereditary Cancer Testing Market, Sub-Segmentation Of Single-Site Genetic Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specific Gene Testing
• Familial Mutation Testing

7. Hereditary Cancer Testing Market Regional And Country Analysis

• 7.1. Global Hereditary Cancer Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hereditary Cancer Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Cancer Testing Market

• 8.1. Asia-Pacific Hereditary Cancer Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Cancer Testing Market

• 9.1. China Hereditary Cancer Testing Market Overview
• 9.2. China Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Cancer Testing Market

• 10.1. India Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Cancer Testing Market

• 11.1. Japan Hereditary Cancer Testing Market Overview
• 11.2. Japan Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Cancer Testing Market

• 12.1. Australia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Cancer Testing Market

• 13.1. Indonesia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Cancer Testing Market

• 14.1. South Korea Hereditary Cancer Testing Market Overview
• 14.2. South Korea Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Cancer Testing Market

• 15.1. Western Europe Hereditary Cancer Testing Market Overview
• 15.2. Western Europe Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Cancer Testing Market

• 16.1. UK Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Cancer Testing Market

• 17.1. Germany Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Cancer Testing Market

• 18.1. France Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Cancer Testing Market

• 19.1. Italy Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Cancer Testing Market

• 20.1. Spain Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Cancer Testing Market

• 21.1. Eastern Europe Hereditary Cancer Testing Market Overview
• 21.2. Eastern Europe Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Cancer Testing Market

• 22.1. Russia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Cancer Testing Market

• 23.1. North America Hereditary Cancer Testing Market Overview
• 23.2. North America Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Cancer Testing Market

• 24.1. USA Hereditary Cancer Testing Market Overview
• 24.2. USA Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Cancer Testing Market

• 25.1. Canada Hereditary Cancer Testing Market Overview
• 25.2. Canada Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Cancer Testing Market

• 26.1. South America Hereditary Cancer Testing Market Overview
• 26.2. South America Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Cancer Testing Market

• 27.1. Brazil Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Cancer Testing Market

• 28.1. Middle East Hereditary Cancer Testing Market Overview
• 28.2. Middle East Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Cancer Testing Market

• 29.1. Africa Hereditary Cancer Testing Market Overview
• 29.2. Africa Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Cancer Testing Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Cancer Testing Market Competitive Landscape
• 30.2. Hereditary Cancer Testing Market Company Profiles
  • 30.2.1. Centogene NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Ambry Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. NeoGenomics Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Quest Diagnostics Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Cancer Testing Market Other Major And Innovative Companies

• 31.1. PreventionGenetics
• 31.2. Fulgent Genetics Inc.
• 31.3. Invitae Corporation
• 31.4. Medical Diagnostic Laboratories LLC
• 31.5. Natera Inc.
• 31.6. Color Health Inc.
• 31.7. CooperSurgical Inc.
• 31.8. OPKO Health Inc.
• 31.9. Illumina Inc.
• 31.10. Laboratory Corporation of America Holdings
• 31.11. Pathway Genomics Corporation
• 31.12. Strand Life Sciences Private Limited
• 31.13. Progenity Inc.
• 31.14. Myogenes Ltd.
• 31.15. Associated Regional and University Pathologists Inc.

32. Global Hereditary Cancer Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Cancer Testing Market

34. Recent Developments In The Hereditary Cancer Testing Market

35. Hereditary Cancer Testing Market High Potential Countries, Segments and Strategies

• 35.1 Hereditary Cancer Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hereditary Cancer Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hereditary Cancer Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer